- Home
- FEBO vs ATOS Comparison
FEBO vs ATOS Comparison
Compare FEBO & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEBO
- ATOS
- Stock Information
- Founded
- FEBO 1993
- ATOS 2009
- Country
- FEBO Hong Kong
- ATOS United States
- Employees
- FEBO N/A
- ATOS N/A
- Industry
- FEBO
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- FEBO
- ATOS Health Care
- Exchange
- FEBO Nasdaq
- ATOS Nasdaq
- Market Cap
- FEBO 136.4M
- ATOS 149.7M
- IPO Year
- FEBO 2023
- ATOS 2012
- Fundamental
- Price
- FEBO $7.85
- ATOS $1.51
- Analyst Decision
- FEBO
- ATOS Strong Buy
- Analyst Count
- FEBO 0
- ATOS 3
- Target Price
- FEBO N/A
- ATOS $6.25
- AVG Volume (30 Days)
- FEBO 144.3K
- ATOS 529.9K
- Earning Date
- FEBO 09-24-2024
- ATOS 08-12-2024
- Dividend Yield
- FEBO N/A
- ATOS N/A
- EPS Growth
- FEBO N/A
- ATOS N/A
- EPS
- FEBO N/A
- ATOS N/A
- Revenue
- FEBO $15,247,349.00
- ATOS N/A
- Revenue This Year
- FEBO N/A
- ATOS N/A
- Revenue Next Year
- FEBO N/A
- ATOS N/A
- P/E Ratio
- FEBO N/A
- ATOS N/A
- Revenue Growth
- FEBO N/A
- ATOS N/A
- 52 Week Low
- FEBO $1.99
- ATOS $0.62
- 52 Week High
- FEBO $17.68
- ATOS $2.31
- Technical
- Relative Strength Index (RSI)
- FEBO 52.67
- ATOS 66.54
- Support Level
- FEBO $5.05
- ATOS $1.30
- Resistance Level
- FEBO $8.50
- ATOS $1.46
- Average True Range (ATR)
- FEBO 0.89
- ATOS 0.07
- MACD
- FEBO 0.49
- ATOS 0.02
- Stochastic Oscillator
- FEBO 91.08
- ATOS 98.04
About FEBO Fenbo Holdings Limited
Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.